Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long-Term Storage at Room Temperature.

What Was Tested

The paper reports a study of DMSO (dimethyl sulfoxide, non-peptide solvent), published as a randomized controlled trial.

Storage of trametinib tablets outside of 2-8°C protected from moisture may lead to loss of dimethyl sulfoxide (DMSO) and adversely impact trametinib bioavailability.

Sixty-five percent of subjects (n = 39/65) were men, and mean (standard deviation) age was 45.6 (11.17) years.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and crossover study.

Because people in this DMSO (dimethyl sulfoxide, non-peptide solvent) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label DMSO (dimethyl sulfoxide, non-peptide solvent) study: the participants and staff both knew the treatment.

In the crossover set-up each of the participants took both DMSO (dimethyl sulfoxide, non-peptide solvent) and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Area Under Curve, Biological Availability, Dimethyl Sulfoxide, Healthy Volunteers, Pyridones, Pyrimidinones and Tablets.

Author keywords: TMT212, bioavailability, storage and trametinib.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of DMSO (dimethyl sulfoxide, non-peptide solvent).

The publication is from 2022 (Clinical pharmacology in drug development), a journal based in United States.

More context: the DMSO (dimethyl sulfoxide, non-peptide solvent) compound page, all human trials.